Comparing first level patent data with value-added patent information: A case study in the pharmaceutical field q
Related Articles
-
Channel strategy and orphan drugs – Courtesy (PMLiVe)
Pharma Live, , Intellectual Property Rights, 0
Channel strategy and orphan drugsA channel strategy is a plan for guiding decisions about a product’s distribution channel, ie...
-
Judge Finds Biosimilar Patent Procedures Optional – Courtesy (Pharma Patent)
Pharma Live, , Intellectual Property Rights, 0
POSTED BY COURTENAY C. BRINCKERHOFF ON 23 MARCH 2015POSTED IN BIOSIMILARSJudge Seeborg of the U.S. District Court for the Northern District of...
-
An exploratory analysis of patent fencing in pharmaceuticals: The case of PDE5 inhibitors
Pharma Live, , Intellectual Property Rights, 0
1-s2-0-s0048733312002582-mainDownload
-
Evaluating and improving orphan drug regulations in Europe: A Delphi policy study
Pharma Live, , Intellectual Property Rights, 0
1-s2-0-s0168851012002461-mainDownload
-
Court Cites Objects Of Invention In Claim Construction – Courtesy (Pharma Patents)
Pharma Live, , Intellectual Property Rights, 0
POSTED BY COURTENAY C. BRINCKERHOFF ON 24 FEBRUARY 2015POSTED IN CLAIM CONSTRUCTION;FEDERAL CIRCUIT DECISIONSPacing Technologies, LLC v. Garmin International, Inc. is one of...
-
The face of the patent is not the ‘‘Whole Story’’: determining effective life of a pharmaceutical patent in the United States
Pharma Live, , Intellectual Property Rights, 0
1-s2-0-s0172219004000675-mainDownload
-
To Study The Scope & Importance Of Amended Patent Act On Indian Pharmaceutical Company With Respect To Innovation
Pharma Live, , Intellectual Property Rights, 0
1-s2-0-s2212567114002469-mainDownload
-
Gene Associated with ALS identified ! – Courtesy(Patent Docs)
Pharma Live, , Intellectual Property Rights, 0
One of the promises of the Human Genome Project was that knowledge of the entirety of the human genetic...